| Autor: |
Lynch CM; Departments of Preclinical Therapeutics, Regulatory Affairs and Nonclinical Development, Bothell, Washington, USA., Hart BW, Grewal IS |
| Jazyk: |
angličtina |
| Zdroj: |
MAbs [MAbs] 2009 Jan-Feb; Vol. 1 (1), pp. 2-11. |
| DOI: |
10.4161/mabs.1.1.7377 |
| Abstrakt: |
Monoclonal antibodies (mAbs) are a well established class of therapeutics as evidenced by a large number of FDA approved mAbs for the treatment of cancers and autoimmune diseases. Monoclonal antibodies that are molecularly engineered for enhanced functions and pharmacokinetic properties are routinely being considered for development by many biotechnology companies. Safety evaluation of current generation of mAbs poses new challenges due to the highly complex nature of engineering aspects and variability induced by the diverse recombinant cell systems to generate them. This review provides a basic outline for nonclinical safety evaluation of therapeutic antibodies. Important considerations for planning a preclinical program, the types of nonclinical safety studies, and a general timeline for their conduct in relation to clinical trials are described. A list of relevant regulatory documents issued by government agencies is also provided. Adoption of these principles will greatly enhance the quality and relevance of the nonclinical safety data generated and will facilitate future development of mAb therapeutics. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
